<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01690520</url>
  </required_header>
  <id_info>
    <org_study_id>2603.00</org_study_id>
    <secondary_id>NCI-2012-01572</secondary_id>
    <secondary_id>2603</secondary_id>
    <secondary_id>2603.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>P50HL110787</secondary_id>
    <nct_id>NCT01690520</nct_id>
  </id_info>
  <brief_title>Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes</brief_title>
  <official_title>Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well donor umbilical cord blood transplant with or
      without ex-vivo expanded cord blood progenitor cells works in treating patients with acute
      myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or
      myelodysplastic syndromes. Giving chemotherapy and total-body irradiation before a donor
      umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the
      patient's immune system from rejecting the donor's cells. When the healthy stem cells and
      ex-vivo expanded cord blood progenitor cells are infused into the patient they may help the
      patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It
      is not yet known whether giving donor umbilical cord blood transplant plus ex-vivo expanded
      cord blood progenitor cells is more effective than giving a donor umbilical cord blood
      transplant alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Compare the time to neutrophil engraftment (absolute neutrophil count [ANC] &gt;= 500) in
      patients receiving a standard of care myeloablative cord blood transplant (CBT) augmented
      with an off-the-shelf pre-expanded and cryopreserved cord blood product to those who do not
      receive the product.

      SECONDARY OBJECTIVES:

      I. Provide initial data on clinical and economic benefit, such as time to platelet
      engraftment, duration of initial hospitalization, transplant-related mortality (TRM), death
      without engraftment, and incidence of severe infections in the first 100 days
      post-transplant.

      II. The kinetics of immune system recovery will also be evaluated in both arms.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      Standard of Care Arm:

      CONDITIONING REGIMEN: One of two possible conditioning regimens is chosen by the attending
      physician: Patients receive fludarabine phosphate intravenously (IV) over 30 minutes on days
      -8 to -6, cyclophosphamide IV on days -7 to -6., and undergo high dose total-body irradiation
      (TBI) twice daily (BID) on days -4 to -1 OR, patients receive fludarabine phosphate IV over
      30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on
      days -5 to -4, and undergo middle intensity TBI once daily (QD) on days -2 to -1.

      TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated umbilical cord blood
      (UCB) transplant on day 0.

      GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive cyclosporine IV over 1 hour
      BID (adults) or thrice daily (TID) (children) or orally (PO) on days -3 to 100 with taper
      beginning on day 101. Patients also receive mycophenolate mofetil (MMF) IV TID on days 0-7
      then may receive MMF PO TID. Patients remain on MMF TID for a minimum of 30 days, and then
      may begin taper if there is no evidence of GVHD and are well-engrafted from one donor unit.

      Experimental Arm:

      CONDITIONING REGIMEN: Patients receive the conditioning regimen chosen by the attending
      physician as in Standard of Care Arm.

      TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day
      0. Patients also receive an infusion of ex vivo-expanded cord blood progenitors at least 4
      hours after completion of UCB transplant.

      GVHD PROPHYLAXIS: Patients receive cyclosporine IV or PO and mycophenolate mofetil IV or PO
      as in Standard of Care Arm.

      After completion of study treatment, patients are followed up periodically for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2012</start_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to engraftment defined as the first 2 consecutive days in which absolute neutrophil count &gt;= 500 in both arms (standard myeloablative cord blood transplantation with and without off-the-shelf expanded cord blood progenitors)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The log-rank test will be used. Groups will be compared using Gray's test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet engraftment (20k)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Groups will be compared using Gray's test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infectious complications</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute and chronic graft versus host disease</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>In vivo persistence of the ex vivo expanded cord blood product</measure>
    <time_frame>Up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of initial hospitalization</measure>
    <time_frame>Up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Infusional toxicity greater than or equal to grade 3</measure>
    <time_frame>Day 0 (day of transplant)</time_frame>
    <description>Toxicities will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.</description>
  </other_outcome>
  <other_outcome>
    <measure>Graft failure (primary and secondary)</measure>
    <time_frame>Up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kinetics of immune system recovery as measured by T and B cell subsets, T cell receptor excision circles, and T cell receptor sequencing</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The kinetics and durability of hematopoietic reconstitution will be assessed and the relative contribution to engraftment of the expanded cord blood product and the unmanipulated unit(s) will be determined by frequent peripheral blood donor chimerism assays.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Erythroid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Acute Megakaryoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Blasts Under 10 Percent of Bone Marrow Nucleated Cells</condition>
  <condition>Blasts Under 5 Percent of Bone Marrow Nucleated Cells</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts</condition>
  <condition>Pancytopenia</condition>
  <condition>Refractory Anemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CONDITIONING REGIMEN: One of two possible conditioning regimens is chosen by the attending physician: Patients receive fludarabine phosphate IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6., and undergo high dose TBI BID on days -4 to -1 OR Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo middle intensity TBI QD on days -2 to -1.
TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0.
GVHD PROPHYLAXIS: Patients receive cyclosporine IV over 1 hour BID (adults) or TID (children) or PO on days -3 to 100 with taper beginning on day 101. Patients also receive MMF IV TID a day on days 0-7 then may receive MMF PO TID. Patients remain on MMF TID for a minimum of 30 days, and then may begin a taper if there is no evidence of GVHD and are well-engrafted from one donor unit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (experimental)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive the conditioning regimen chosen by the attending physician as in Standard of Care Arm.
TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0. Patients also undergo infusion of ex vivo-expanded cord blood progenitor cell infusion at least 4 hours after completion of UCB transplant.
GVHD PROPHYLAXIS: Patients receive cyclosporine IV or PO and mycophenolate mofetil IV or PO as in Standard of Care Arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (experimental)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (experimental)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Double-Unit Umbilical Cord Blood Transplantation</intervention_name>
    <description>Undergo double-unit unmanipulated umbilical cord blood transplant</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (experimental)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (experimental)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (experimental)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (experimental)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (experimental)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (experimental)</arm_group_label>
    <other_name>1,1',1''-Phosphinothioylidynetrisaziridine</other_name>
    <other_name>Girostan</other_name>
    <other_name>N,N', N''-Triethylenethiophosphoramide</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Tio-tef</other_name>
    <other_name>Triethylene thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>Tris(1-aziridinyl)phosphine sulfide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo high dose or middle intensity TBI</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (experimental)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood Transplantation</intervention_name>
    <description>Undergo single-unit unmanipulated umbilical cord blood transplant</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (experimental)</arm_group_label>
    <other_name>Cord Blood Transplantation</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age criteria:

               -  High dose TBI regimen: 6 months to =&lt; 45 years

               -  Middle intensity TBI regimen: 6 months to =&lt; 65 years

               -  Conditioning regimen selection should be based on the underlying disease,
                  presence of minimal residual disease (MRD), age, co-morbidities, attending
                  physician, and site preference; conditioning regimen will not require
                  stratification of the randomization due to heterogeneity in the cohort of
                  eligible patients.

          -  Acute myeloid leukemia, including biphenotypic acute leukemia or mixed-lineage
             leukemia

               -  All patients must have acute myeloid leukemia (AML) that is considered best
                  treated by stem cell transplant by the referring physician and the attending
                  transplant physician

               -  All patients must be in complete remission (CR) as defined by &lt; 5% blasts by
                  morphology/flow cytometry in a representative bone marrow sample with cellularity
                  &gt;= 15% for age

               -  Patients in which adequate marrow/biopsy specimens cannot be obtained to
                  determine remission status by morphologic assessment, but have fulfilled criteria
                  of remission by flow cytometry, recovery of peripheral blood counts with no
                  circulating blasts, and/or normal cytogenetics (if applicable) may still be
                  eligible; reasonable attempts must be made to obtain an adequate specimen for
                  morphologic assessment, including possible repeat procedures; these patients must
                  be discussed with the principal investigator prior to enrollment

          -  Acute lymphoblastic leukemia, including biphenotypic acute leukemia or mixed-lineage
             leukemia

               -  High risk first complete remission (CR1) (for example, but not limited to:
                  t(9;22), t(1;19), t(4;11) or other mixed-lineage leukemia [MLL] rearrangements,
                  hypodiploid); or high risk (HR) as defined by referring institution treatment
                  protocol greater than 1 cycle to obtain CR; second complete remission (CR2) or
                  greater

               -  All patients must be in CR as defined by &lt; 5% blasts by morphology/flow cytometry
                  in a representative bone marrow sample with cellularity &gt;= 15% for age

               -  Patients in which adequate marrow/biopsy specimens cannot be obtained to
                  determine remission status by morphologic assessment, but have fulfilled criteria
                  of remission by flow cytometry, recovery of peripheral blood counts with no
                  circulating blasts, and/or normal cytogenetics (if applicable) may still be
                  eligible; reasonable attempts must be made to obtain an adequate specimen for
                  morphologic assessment, including possible repeat procedures; these patients must
                  be discussed with the principal investigator prior to enrollment

          -  Chronic myelogenous leukemia excluding refractory blast crisis; to be eligible in
             first chronic phase (CP1) patient must have failed or be intolerant to tyrosine kinase
             inhibitor therapy

          -  Myelodysplasia (MDS) International Prognostic Scoring System (IPSS) intermediate
             (Int)-2 or high risk (i.e., refractory anemia with excess blasts [RAEB], refractory
             anemia with excess blasts in transformation [RAEBt]) or refractory anemia with severe
             pancytopenia or high risk cytogenetics; blasts must be &lt; 10% by a representative bone
             marrow aspirate morphology

          -  Karnofsky (&gt;= 16 years old) &gt;= 70 or Eastern Cooperative Oncology Group (ECOG) 0-1

          -  Lansky (&lt; 16 years old) &gt;= 60

          -  Adults: calculated creatinine clearance must be &gt; 60 mL and serum creatinine =&lt; 2
             mg/dL

          -  Children (&lt; 18 years old): calculated creatinine clearance must be &gt; 60 mL/min

          -  Total serum bilirubin must be &lt; 3 mg/dL unless the elevation is thought to be due to
             Gilbert's disease or hemolysis

          -  Transaminases must be &lt; 3 x the upper limit of normal per reference values of
             referring institution

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) corrected &gt; 60% normal

          -  For pediatric patients unable to perform pulmonary function tests, oxygen (O2)
             saturation &gt; 92% on room air

          -  May not be on supplemental oxygen

          -  Left ventricular ejection fraction &gt; 45% OR

          -  Shortening fraction &gt; 26%

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Uncontrolled viral or bacterial infection at the time of study enrollment

          -  Active or recent (prior 6 month) invasive fungal infection without infectious disease
             (ID) consult and approval

          -  History of human immunodeficiency virus (HIV) infection

          -  Pregnant or breastfeeding

          -  Prior myeloablative transplant containing full dose TBI (greater than 8 Gy)

          -  Central nervous system (CNS) leukemic involvement not clearing with intrathecal
             chemotherapy and/or cranial radiation prior to initiation of conditioning; diagnostic
             lumbar puncture is to be performed per protocol

          -  Patients &gt;= 45 years: comorbidity score of 5 or higher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Milano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chatchada Karanes</last_name>
      <phone>626-359-8111</phone>
      <phone_ext>62691</phone_ext>
      <email>becomingapatient@coh.org</email>
    </contact>
    <investigator>
      <last_name>Chatchada Karanes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Rezvani</last_name>
      <phone>650-725-4077</phone>
      <email>arezvani@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Rezvani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer R. Willert</last_name>
      <phone>415-476-2188</phone>
    </contact>
    <investigator>
      <last_name>Jennifer R. Willert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80217-3364</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan A. Gutman</last_name>
      <phone>720-848-0644</phone>
      <email>jonathan.gutman@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan A. Gutman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine N. Duncan</last_name>
      <phone>617-632-6255</phone>
      <email>christine_duncan@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Christine N. Duncan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alla Keyzner</last_name>
      <phone>646-942-8201</phone>
      <email>alla.keyzner@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Alla Keyzner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Kurtzberg</last_name>
      <phone>919-668-1100</phone>
      <email>kurtz001@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Joanne Kurtzberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rabi Hanna</last_name>
      <phone>216-444-0663</phone>
      <email>hannar2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Rabi Hanna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Milano</last_name>
      <phone>206-667-5925</phone>
      <email>fmilano@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Filippo Milano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2012</study_first_submitted>
  <study_first_submitted_qc>September 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

